Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
43.5 CHF | +0.93% | +5.77% | +21.95% |
May. 03 | Basilea Reports Presentation of New Data for Ceftobiprole (Zevtera®) At Escmid Global 2024 | CI |
Apr. 09 | Basilea Pharmaceutica Receives Grant for Antibiotics Program | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.95% | 573M | |
+26.37% | 48.16B | |
-1.01% | 41.73B | |
+41.93% | 41.03B | |
-5.31% | 28.77B | |
+9.34% | 25.59B | |
-21.69% | 18.96B | |
+6.23% | 12.92B | |
+26.99% | 12.03B | |
-3.38% | 11.77B |
- Stock Market
- Equities
- BSLN Stock
- News Basilea Pharmaceutica AG
- Basilea Pharmaceutica : Edison Investment Research Lowers Price Target on Basilea Pharmaceutica